

# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO	).	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/807,710 03/23/2004		03/23/2004	Teng-Kuei Yang	14311 B	5637
36672	7590	06/16/2006		EXAMINER	
CHARLE 90 JOHN S		KLEY, ESQ.		SHAMEEM,	GOLAM M
THIRD FL				ART UNIT	PAPER NUMBER
NEW YORK, NY 10038				1626	
				DATE MAILED: 06/16/2000	4

Please find below and/or attached an Office communication concerning this application or proceeding.

<del></del>		Application No.	Applicant(s)					
		10/807,710	YANG ET AL.					
	Office Action Summary	Examiner	Art Unit					
		Golam M. M. Shameem, Ph.D.	1626					
Period fo	The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply							
A SH WHIC - Exter after - If NO - Failu Any	ORTENED STATUTORY PERIOD FOR REPLY CHEVER IS LONGER, FROM THE MAILING DANSIONS of time may be available under the provisions of 37 CFR 1.13 SIX (6) MONTHS from the mailing date of this communication. Period for reply is specified above, the maximum statutory period were to reply within the set or extended period for reply will, by statute, reply received by the Office later than three months after the mailing ed patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be tim rill apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE	I. lely filed the mailing date of this communication. O (35 U.S.C. § 133).					
Status								
2a) <u></u>	Responsive to communication(s) filed on <u>27 Ap</u> This action is <b>FINAL</b> . 2b) This Since this application is in condition for allowant closed in accordance with the practice under E	action is non-final. nce except for formal matters, pro						
Dispositi	on of Claims							
<ul> <li>4) ☐ Claim(s) 1-3 and 9-17 is/are pending in the application.</li> <li>4a) Of the above claim(s) is/are withdrawn from consideration.</li> <li>5) ☐ Claim(s) is/are allowed.</li> <li>6) ☐ Claim(s) 1-3 and 9-17 is/are rejected.</li> <li>7) ☐ Claim(s) is/are objected to.</li> <li>8) ☐ Claim(s) are subject to restriction and/or election requirement.</li> </ul>								
Applicati	on Papers							
10)□	The specification is objected to by the Examiner The drawing(s) filed on is/are: a) access applicant may not request that any objection to the confection to the confection to the cather of the confection of the cather are declaration is objected to by the Examiner.	epted or b) objected to by the Edrawing(s) be held in abeyance. See on is required if the drawing(s) is objected	37 CFR 1.85(a). ected to. See 37 CFR 1.121(d).					
Priority u	ınder 35 U.S.C. § 119							
<ul> <li>12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).</li> <li>a) All b) Some * c) None of:</li> <li>1. Certified copies of the priority documents have been received.</li> <li>2. Certified copies of the priority documents have been received in Application No.</li> <li>3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).</li> <li>* See the attached detailed Office action for a list of the certified copies not received.</li> </ul>								
2) D Notice 3) D Inform	e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (PTO-948) nation Disclosure Statement(s) (PTO-1449 or PTO/SB/08) No(s)/Mail Date	4) Interview Summary ( Paper No(s)/Mail Dat 5) Notice of Informal Pa 6) Other:	te					

#### **DETAILED ACTION**

#### Priority

This application is a CIP of 10/039,557 01/08/2002, is acknowledged.

### Status of Claims

Claims 1-3 and 9-17 are currently pending in the application. Claims 4-8 were canceled.

Receipt is acknowledged of Applicant's amendment / response filed on April 27, 2006 and that has been entered.

# Response to Election/Restriction

In response to the restriction requirement, Applicants have elected Group IV, which includes claims 1-3 and 9-17 drawn to compounds and the elected species as set forth (Response, page 4) with traverse is acknowledged. Since Invention Groups I-III and V fall within the scope of elected invention Group IV, Examiner will rejoin and examine all Groups I-V together and therefore, the restriction requirement has been withdrawn and Applicants arguments are rendered moot in view of the present Office action.

# Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claims 1-3 and 9-17 are rejected under 35 U.S.C. § 102(b) as being anticipated by Trost et al (1982). Applicant claims aminothiol compounds and their method of uses (catalyzing an asymmetric addition reaction) thereof. Trost et al also disclose the synthesis of substituted

Application/Control Number: 10/807,710

Art Unit: 1626

pyrrolidine derivative which anticipates the instantly claimed invention, wherein R<sup>1</sup> is alkyl of C1-C9 (such as, n-butyl), R<sup>2</sup> is alkyl of C1-C9 (such as, n-butyl), R<sup>3</sup>, R<sup>4</sup> and N form pyrrolidinyl, and R<sup>5</sup> is methyl (Me) [STN International, HCAPLUS database, RN 81230-62-8, a copy is provided with this Office action], which reads on the instantly claimed compounds.

### Double Patenting

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. See *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and, *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.130(b).

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

Claims 1-3 and 9-17 are subjected for rejection under the judicially created doctrine of obviousness-type double patenting, as being unpatentable over claim 1 of US 6,861,536, since the claims, if allowed, would improperly extend the "right to exclude" already granted in the patent. Although the conflicting claims are not identical, they are not patentably distinct from each other because all sets of claims are drawn to the same art recognized subject matter. A reference anticipating one set of claims will render the other obvious and it would have been obvious to one of ordinary skill in the art at the time of the invention was made since Yang *et al* teach the generic compounds which are similar to the instantly claimed compounds.

The subject matter claimed in the instant application is fully disclosed and covered in US 6,861,536. Therefore, the disclosure of Yang et al that teach several permutation and combinations (including various Markush variable substitutions, such as R<sup>3</sup>, R<sup>4</sup> and N form a

five-membered heterocycle pyrrolidine), which would easily place Applicant's invention in possession of the public at the time of Applicant's invention was filed. The indiscriminate selection of "some" among "many" is *prima facie* obvious, *In re Lemin*, 141 USPQ 814 (1964). Therefore, in the instant case, one skilled in the chemical art would be motivated to choose to make six-membered heterocycle (such as piperidyl, morpholinyl etc.) in permutation and combinations in core structure to obtain the desired products in view of the known teaching of the art. The claimed compounds are so closely related structurally to the homologous and /or analogous compounds of the reference as to be structurally obvious therefore in the absence of any unobviousness or unexpected properties. Moreover, any other differences are but obvious structural modifications, which would be apparent to one skilled in the chemical art that can use similar substitutions, would expect to have the same or essentially the same results. Therefore, in looking at the instant claimed compounds as a whole, the claimed compounds would have been suggested to one skilled in the art unless unobvious or unexpected results can be shown.

#### Telephone Inquiry

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Golam Shameem, Ph.D. whose telephone number is (571) 272-0706. The examiner can normally be reached on Monday-Thursday from 6:30 AM - 5:00 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Joseph McKane, can be reached at (571) 272-0699. The Unofficial fax phone number for this Group is (703) 308-7921. The Official fax phone number for this Group is 571-273-8300.

Art Unit: 1626

When filing a FAX in Technology Center 1600, please indicate in the Header (upper

right) "Official" for papers that are to be entered into the file, and "Unofficial" for draft

documents and other communications with the PTO that are not for entry into the file of the

application. This will expedite processing of your papers.

Communications via Internet e-mail regarding this application, other than those under 35

U.S.C. 132 or which otherwise require a signature, may be used by the applicant and should be

addressed to [joseph.mcKane@uspto.gov]. All Internet e-mail communications will be made of

record in the application file. PTO employees will not communicate with applicant via Internet

e-mail where sensitive data will be exchanged or where there exists a possibility that sensitive

data could be identified unless there is of record an express waiver of the confidentiality

requirements under 35 U.S.C. 122 by the applicant. See the Interim Internet Usage Policy

published by the Patent and Trademark Office Official Gazette on February 25, 1997 at 1195 OG

89.

Any inquiry of a general nature or relating to the status of this application should be

directed to the Group receptionist, whose telephone number is (571) 272-1600.

Golam M M Shameem, Ph.D.

Primary Examiner

Art Unit 1626,

Technology Center 1600

GOLAM M. M. SHAMEEM, PH.D PRIMARY EXAMINER

June 06, 2006